Leo Lee

Mr Lee brings more than 20 years experience in pharmaceutical innovation, commercialisation, regulation and policy development and has worked in North America and Asia. Mr Lee currently serves as Country President, Japan, for Novartis and prior to his CEO role at Regeneus, he was President, Japan, for Merck KGaA. Prior to this, he served as President, Japan, for Allergan plc, a global pharmaceutical company. Leo has held sales and commercial roles in Merck & Co., IQVIA and Accelrys, Inc.

Company and Role

Company
Title
Tenure
Since
RGS
Regeneus Ltd
  • Non-Executive Director
5yrs, 1mthJan 2019

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
RGS
Regeneus Ltd
29/09/23N/A15,890,8931,250,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
RGS
Regeneus Ltd
13/11/20
Expiry
9,000,000$0.115$1,035,000Options expired
RGS
Regeneus Ltd
01/09/20
Transfer
13,511,000$0.180$2,431,980Off-market transfer
RGS
Regeneus Ltd
01/09/20
Transfer
13,511,000$0.180$2,431,980Off-market transfer
RGS
Regeneus Ltd
01/09/20
Buy
2,379,893$0.182$432,079On-market trade
RGS
Regeneus Ltd
31/01/20
Expiry
1,250,000$0.080$100,000Options expired